<DOC>
	<DOC>NCT00316212</DOC>
	<brief_summary>The purpose of this trial is to identify a dose or doses of INS50589 intravenous infusion that are well-tolerated and which reduce postoperative bleeding and blood product transfusion.</brief_summary>
	<brief_title>Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Grafting (CABG) Involving Cardiopulmonary Bypass</brief_title>
	<detailed_description />
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>INS 50589</mesh_term>
	<criteria>Are scheduled for primary CABG by median sternotomy involving cardiopulmonary bypass Willing to receive allogeneic blood product transfusions during and after surgery Have had previous cardiac surgery Have had previous median sternotomy Have tendency for bleeding or family history of bleeding Have an abnormally low platelet count Have received certain anticoagulant or antiplatelet medications within a specified time period prior to the scheduled CABG surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Coronary Artery Bypass Graft Surgery involving Cardiopulmonary Bypass</keyword>
</DOC>